Celsion Stock Price, News & Analysis (NASDAQ:CLSN)

$2.20 -0.06 (-2.65 %)
(As of 02/18/2018 01:33 PM ET)
Previous Close$2.20
Today's Range$2.18 - $2.33
52-Week Range$1.24 - $6.06
Volume216,946 shs
Average Volume339,103 shs
Market Capitalization$35.34 million
P/E Ratio-0.38
Dividend YieldN/A
Beta1.81

About Celsion (NASDAQ:CLSN)

Celsion logoCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CLSN
CUSIPN/A
Phone+1-609-8969100

Debt

Debt-to-Equity RatioN/A
Current Ratio0.46%
Quick Ratio0.46%

Price-To-Earnings

Trailing P/E Ratio-0.37542662116041
Forward P/E Ratio-0.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales78.01
Cash FlowN/A
Price / CashN/A
Book Value$3.01 per share
Price / Book0.73

Profitability

Trailing EPS($5.86)
Net Income$-22,050,000.00
Net Margins-4,292.80%
Return on Equity-282.94%
Return on Assets-59.69%

Miscellaneous

Employees19
Outstanding Shares17,730,000

Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Celsion's stock reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings data on Thursday, May, 18th. The biotechnology company reported ($1.64) EPS for the quarter, missing the Zacks' consensus estimate of ($1.30) by $0.34. The biotechnology company earned $0.13 million during the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%. View Celsion's Earnings History.

When will Celsion make its next earnings announcement?

Celsion is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Celsion.

Where is Celsion's stock going? Where will Celsion's stock price be in 2018?

4 Wall Street analysts have issued 1-year target prices for Celsion's stock. Their predictions range from $7.00 to $21.00. On average, they expect Celsion's stock price to reach $14.50 in the next year. View Analyst Ratings for Celsion.

What are Wall Street analysts saying about Celsion stock?

Here are some recent quotes from research analysts about Celsion stock:

  • 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (1/11/2018)
  • 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)

Who are some of Celsion's key competitors?

Who are Celsion's key executives?

Celsion's management team includes the folowing people:

  • Jeffrey Wayne Church CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer (Age 58)
  • Khursheed Anwer Ph.D., Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy (Age 55)
  • Nicholas Borys M.D., Senior Vice President and Chief Medical Officer (Age 55)
  • Michael H. Tardugno, Executive Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Donald Braun Ph.D., Independent Director
  • Pok Yu Chow Ph.D., Independent Director (Age 63)
  • Frederick J. Fritz, Independent Director (Age 64)
  • Robert W. Hooper, Independent Director (Age 68)
  • Alberto R. Martinez M.D., Independent Director (Age 65)

Who owns Celsion stock?

Celsion's stock is owned by a variety of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (4.99%), SABBY MANAGEMENT, LLC (4.99%), SABBY MANAGEMENT, LLC (4.99%) and Virtu Financial LLC (0.24%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion.

Who bought Celsion stock? Who is buying Celsion stock?

Celsion's stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Insider Buying and Selling for Celsion.

How do I buy Celsion stock?

Shares of Celsion can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of Celsion stock can currently be purchased for approximately $2.20.

How big of a company is Celsion?

Celsion has a market capitalization of $35.34 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-22,050,000.00 in net income (profit) each year or ($5.86) on an earnings per share basis. Celsion employs 19 workers across the globe.

How can I contact Celsion?

Celsion's mailing address is 997 Lenox Dr Ste 100, LAWRENCE TOWNSHIP, NJ 08648-2317, United States. The biotechnology company can be reached via phone at +1-609-8969100 or via email at [email protected]


MarketBeat Community Rating for Celsion (CLSN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celsion (NASDAQ:CLSN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.50$14.50$16.33$32.67
Price Target Upside: 577.57% upside577.57% upside169.53% upside2,137.44% upside

Celsion (NASDAQ:CLSN) Consensus Price Target History

Price Target History for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017OppenheimerInitiated CoverageOutperform$9.00N/AView Rating Details
10/4/2017Maxim GroupUpgradeHold -> Buy$7.00HighView Rating Details
4/10/2017Rodman & RenshawReiterated RatingBuy$21.00HighView Rating Details
4/10/2017HC WainwrightReiterated RatingBuy$21.00HighView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Celsion (NASDAQ:CLSN) Earnings History and Estimates Chart

Earnings by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/14/2017Q3 2017($0.56)($0.39)$0.13 million$0.13 millionViewN/AView Earnings Details
8/14/2017Q2 2017($1.10)($0.79)$0.13 million$0.13 millionViewN/AView Earnings Details
5/18/2017Q1 2017($1.30)($1.64)$0.13 million$0.13 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.24)($1.96)$0.13 million$0.13 millionViewN/AView Earnings Details
11/10/2016Q3 2016($2.66)($3.22)$0.13 million$0.13 millionViewN/AView Earnings Details
8/15/2016Q2($2.94)($2.66)$0.13 million$0.13 millionViewListenView Earnings Details
5/16/2016Q116($2.94)($3.36)$0.13 million$0.13 millionViewListenView Earnings Details
3/30/2016Q415($3.36)($3.36)$0.16 million$0.13 millionViewListenView Earnings Details
11/5/2015Q315($3.64)($2.80)$0.14 million$0.13 millionViewN/AView Earnings Details
8/10/2015Q215($4.34)($3.78)$0.16 million$0.13 millionViewListenView Earnings Details
5/12/2015Q1($4.62)($4.76)$0.13 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q4 2014($5.04)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
11/11/2014Q3 2014($4.20)($4.90)$0.16 million$0.13 millionViewN/AView Earnings Details
8/7/2014Q214($3.92)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
5/8/2014Q1 2014($2.80)($4.62)$0.13 million$0.13 millionViewN/AView Earnings Details
3/13/2014($3.92)($2.66)$0.13 million$0.13 millionViewN/AView Earnings Details
11/12/2013Q3($3.15)($4.20)$0.13 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.98)$0.14$0.13 millionViewN/AView Earnings Details
5/9/2013Q1 2013($2.24)($1.68)$0.38 million$0.13 millionViewN/AView Earnings Details
3/18/2013Q4 2012($10.72)($13.24)ViewN/AView Earnings Details
11/12/2012Q312($2.38)($2.52)ViewN/AView Earnings Details
8/14/2012Q2 2012($11.98)($11.60)ViewN/AView Earnings Details
5/15/2012Q1 2012($13.24)($11.72)ViewN/AView Earnings Details
3/15/2012Q4 2011($13.87)($11.35)ViewN/AView Earnings Details
11/10/2011Q3 2011($16.39)($16.01)ViewN/AView Earnings Details
8/9/2011Q2 2011($24.46)ViewN/AView Earnings Details
5/12/2011Q1 2011($18.41)ViewN/AView Earnings Details
3/25/2011Q4 2010($26.47)ViewN/AView Earnings Details
11/15/2010Q3 2010($23.32)($24.08)ViewN/AView Earnings Details
8/3/2010Q2 2010($23.95)($23.01)ViewN/AView Earnings Details
5/4/2010Q1 2010($20.17)($23.64)ViewN/AView Earnings Details
2/17/2010Q4 2009($22.69)($11.85)ViewN/AView Earnings Details
11/10/2009Q3 2009($29.37)ViewN/AView Earnings Details
8/5/2009Q2 2009($28.36)ViewN/AView Earnings Details
5/12/2009Q1 2009($22.38)ViewN/AView Earnings Details
3/3/2009Q4 2008($5.80)ViewN/AView Earnings Details
11/13/2008Q3 2008($26.98)ViewN/AView Earnings Details
8/18/2008Q2 2008($15.06)ViewN/AView Earnings Details
5/8/2008Q1 2008($25.34)ViewN/AView Earnings Details
2/21/2008Q4 2007($15.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celsion (NASDAQ:CLSN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.38)($0.38)($0.38)
Q4 20181($0.30)($0.30)($0.30)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion (NASDAQ:CLSN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celsion (NASDAQ CLSN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 3.63%
Insider Trades by Quarter for Celsion (NASDAQ:CLSN)
Institutional Ownership by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2017Frederick J FritzDirectorBuy13,000$1.89$24,570.009,841View SEC Filing  
2/21/2017Alberto R Martinez JrDirectorBuy35,000$0.23$8,050.00180,081View SEC Filing  
2/15/2017Alberto R Martinez JrDirectorBuy45,000$0.22$9,900.00145,081View SEC Filing  
11/14/2016Alberto R Martinez JrDirectorBuy10,000$0.86$8,600.00100,081View SEC Filing  
11/11/2016Alberto R Martinez JrDirectorBuy10,000$0.91$9,100.0090,081View SEC Filing  
10/7/2016Michael H TardugnoChairmanBuy10,000$1.14$11,400.00143,021View SEC Filing  
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.0080,081View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.0075,081View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00128,021View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00120,521View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00117,521View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.0070,081View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00115,521View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00111,021View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.482,421,867View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.002,442,423View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.002,462,423View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.002,472,423View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.0021,331View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.0057,521View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.0053,521View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.0014,331View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.0051,000View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00228,285View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celsion (NASDAQ CLSN) News Headlines

Source:
DateHeadline
 Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00 Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - February 15 at 3:36 AM
Zacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPSZacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPS
www.americanbankingnews.com - February 13 at 3:12 PM
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Associations 12th Annual ... - GlobeNewswire (press release)Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:01 AM
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific MeetingCelsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting
finance.yahoo.com - February 12 at 3:21 PM
Celsion Co. (CLSN) Receives Average Rating of "Buy" from BrokeragesCelsion Co. (CLSN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 4 at 8:02 AM
Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - January 29 at 3:46 AM
-$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter-$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - January 27 at 5:20 PM
Celsion Corporation Provides Corporate Update and 2018 OutlookCelsion Corporation Provides Corporate Update and 2018 Outlook
finance.yahoo.com - January 18 at 10:38 AM
Celsion (CLSN) Downgraded to Hold at Zacks Investment ResearchCelsion (CLSN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 11 at 7:48 PM
Zacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per ShareZacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - January 10 at 5:28 PM
Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by BrokeragesCelsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 10 at 8:18 AM
Celsions Phase I/II Cancer Study Initiation Gets FDA Nod - NasdaqCelsion's Phase I/II Cancer Study Initiation Gets FDA Nod - Nasdaq
www.nasdaq.com - January 5 at 4:54 PM
FDA Win Sends Celsion Corporation (CLSN) Shares Higher - Investorplace.comFDA Win Sends Celsion Corporation (CLSN) Shares Higher - Investorplace.com
investorplace.com - January 5 at 4:54 PM
FDA Win Sends Celsion Corporation (CLSN) Shares HigherFDA Win Sends Celsion Corporation (CLSN) Shares Higher
investorplace.com - January 4 at 4:14 PM
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian CancerCelsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
finance.yahoo.com - January 4 at 9:41 AM
Celsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trialCelsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trial
finance.yahoo.com - January 4 at 9:41 AM
Celsion Corporation (CLSN) Shares on the Rise; Here’s WhyCelsion Corporation (CLSN) Shares on the Rise; Here’s Why
finance.yahoo.com - January 4 at 9:41 AM
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision DrillingZacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
finance.yahoo.com - January 4 at 9:41 AM
ETFs with exposure to Celsion Corp. : January 2, 2018ETFs with exposure to Celsion Corp. : January 2, 2018
finance.yahoo.com - January 2 at 6:24 PM
Zacks: Brokerages Anticipate Celsion Co. (CLSN) Will Post Quarterly Sales of $130,000.00Zacks: Brokerages Anticipate Celsion Co. (CLSN) Will Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - December 27 at 1:40 PM
 Brokerages Anticipate Celsion Co. (CLSN) to Post -$0.31 EPS Brokerages Anticipate Celsion Co. (CLSN) to Post -$0.31 EPS
www.americanbankingnews.com - December 25 at 5:08 AM
ETFs with exposure to Celsion Corp. : December 22, 2017ETFs with exposure to Celsion Corp. : December 22, 2017
finance.yahoo.com - December 22 at 8:55 PM
Celsion (CLSN) Upgraded to "Hold" by Zacks Investment ResearchCelsion (CLSN) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 19 at 9:02 PM
Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by AnalystsCelsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM
Celsion Co. (CLSN) Short Interest UpdateCelsion Co. (CLSN) Short Interest Update
www.americanbankingnews.com - December 15 at 3:08 AM
Financial Review: Celsion (CLSN) vs. The CompetitionFinancial Review: Celsion (CLSN) vs. The Competition
www.americanbankingnews.com - December 11 at 11:22 PM
ETFs with exposure to Celsion Corp. : December 11, 2017ETFs with exposure to Celsion Corp. : December 11, 2017
finance.yahoo.com - December 11 at 5:19 PM
Celsion (CLSN) Upgraded to "Sell" at ValuEngineCelsion (CLSN) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - December 9 at 12:08 PM
Adaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical ContrastAdaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical Contrast
www.americanbankingnews.com - December 9 at 5:30 AM
Comparing Celsion (CLSN) & Its RivalsComparing Celsion (CLSN) & Its Rivals
www.americanbankingnews.com - December 5 at 11:30 AM
ETFs with exposure to Celsion Corp. : November 30, 2017ETFs with exposure to Celsion Corp. : November 30, 2017
finance.yahoo.com - November 30 at 5:04 PM
Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:50 AM
Celsion Corporation (CLSN) Short Interest UpdateCelsion Corporation (CLSN) Short Interest Update
www.americanbankingnews.com - November 29 at 2:08 AM
Celsion Delivering Doxorubicin To Cancer TissuesCelsion Delivering Doxorubicin To Cancer Tissues
seekingalpha.com - November 23 at 4:02 PM
Brokers Offer Predictions for Celsion Corporations Q4 2017 Earnings (CLSN)Brokers Offer Predictions for Celsion Corporation's Q4 2017 Earnings (CLSN)
www.americanbankingnews.com - November 23 at 9:58 AM
Celsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours - Seeking AlphaCelsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours - Seeking Alpha
seekingalpha.com - November 21 at 10:26 PM
Why Celsion Could Still More Than Double on Top of Good NewsWhy Celsion Could Still More Than Double on Top of Good News
247wallst.com - November 21 at 5:26 PM
Here’s Why Celsion Corporation Draws a Vote of Confidence from OppenheimerHere’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer
finance.yahoo.com - November 21 at 5:26 PM
Celsion Corporation (CLSN) Given Average Recommendation of "Buy" by AnalystsCelsion Corporation (CLSN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 21 at 3:38 PM
Celsion Corporation (CLSN) Now Covered by Oppenheimer Holdings, Inc.Celsion Corporation (CLSN) Now Covered by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 21 at 2:38 PM
Celsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound - StreetInsider.comCelsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound - StreetInsider.com
www.streetinsider.com - November 21 at 4:25 AM
Celsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic UltrasoundCelsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound
www.streetinsider.com - November 20 at 6:23 PM
Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic UltrasoundCelsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic Ultrasound
finance.yahoo.com - November 20 at 6:23 PM
Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours StudyCelsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study
finance.yahoo.com - November 20 at 6:23 PM
Reviewing Relypsa (RLYP) and Celsion Corporation (CLSN)Reviewing Relypsa (RLYP) and Celsion Corporation (CLSN)
www.americanbankingnews.com - November 19 at 5:34 PM
Celsion Corporation (CLSN) Cut to "Strong Sell" at ValuEngineCelsion Corporation (CLSN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - November 15 at 10:56 PM
Celsion (CLSN) Files Immunotherapy Clinical Protocol for Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian ... - StreetInsider.comCelsion (CLSN) Files Immunotherapy Clinical Protocol for Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian ... - StreetInsider.com
www.streetinsider.com - November 15 at 12:13 AM
Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 15 at 12:13 AM
Edited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMTEdited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMT
finance.yahoo.com - November 15 at 12:13 AM
Celsion Corporation to Host Earnings CallCelsion Corporation to Host Earnings Call
finance.yahoo.com - November 14 at 5:48 PM

SEC Filings

Celsion (NASDAQ:CLSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celsion (NASDAQ:CLSN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celsion (NASDAQ CLSN) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.